Biogen and Sage enter into an agreement to jointly develop and commercialize zuranolone and SAGE-324 in the U.S. Biogen to receive exclusive license to develop and commercialize zuranolone and SAGE-324 outside of the U.S. , excluding rights to zuranolone in Japan , Taiwan and South Korea Sage

Ongoing zuranolone Phase 3 pivotal trials in major depression and postpartum depression progressing well; expect to initiate dosing in CORAL Study in 4Q 2020 Continued execution across brain health franchises highlighted during 2 nd annual FutureCast event First patient dosed in PARADIGM Study

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 2, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 22, 2020-- Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that Jeff Jonas , M.D.,

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 19, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast

Zuranolone was generally well-tolerated at the 30 mg dose and by the initial patients treated with the 50 mg dose with an adverse event profile consistent with that seen in earlier trials Nearly half of trial participants with positive response to initial 14-day course of zuranolone 30 mg did not

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 1, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the addition of Barry Greene

Thinking differently about thinking – Development plans for SAGE-718 focused on executive function across multiple indications Early learnings from studies of other compounds created multi-faceted insights for SAGE-324 program in essential tremor Interview with investigator from SHORELINE study

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 1, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 20, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that it will host Sage